ITGA6-targeted dye for liver cancer surgery guidance
Part of Cancer, Digestive system clinical trials.
This trial uses a special dye that lights up during surgery to help doctors see and remove liver cancer cells that have a specific protein (ITGA6). It aims to make surgery more precise and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer).
- You are scheduled to have surgery to remove part of your liver (hepatectomy).
- Your liver function is good (Child-Pugh class A).
- Your tumor has high levels of a protein called ITGA6 (confirmed by a test before surgery).
- You are between 18 and 80 years old, and your doctor expects you to live at least 6 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a special fluorescent dye that targets GPC3 can help surgeons find liver cancer more clearly during an operation. It may improve how accurately tumor tissue is identified while you have surgery for hepatocellular carcinoma.
This trial tests whether giving medicine directly into the liver blood vessels before surgery can improve survival for people with liver cancer that has a blockage (tumor in the portal vein). It compares this approach plus surgery versus surgery alone in a randomized study.
This study tests a CT-guided method to find and precisely locate very small liver cancer spots before surgery. It may help surgeons remove the tumor more accurately when standard scans cannot clearly see it.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
This trial tests a new dye that helps surgeons see the edges of stomach cancer more clearly during surgery. It may help ensure all cancer is removed.
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.